Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Wynn, Daniel, MD, Kaufman, Michael, MD, Montalban, Xavier, MD, Vollmer, Timothy, MD, Simon, Jack, MD, Elkins, Jacob, MD, O'Neill, Gilmore, MD, Neyer, Lauri, PhD, Sheridan, James, PhD, Wang, Chungchi, PhD, Fong, Alice, PharmD, Rose, John W, MD
Published in Lancet neurology (01.04.2010)
Published in Lancet neurology (01.04.2010)
Get full text
Journal Article
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Kappos, Ludwig, MD, Freedman, Mark S, MD, Polman, Chris H, MD, Edan, Gilles, MD, Hartung, Hans-Peter, MD, Miller, David H, MD, Montalbán, Xavier, MD, Barkhof, Frederik, MD, Radü, Ernst-Wilhelm, MD, Metzig, Carola, MD, Bauer, Lars, MD, Lanius, Vivian, PhD, Sandbrink, Rupert, MD, Pohl, Christoph, MD
Published in Lancet neurology (01.11.2009)
Published in Lancet neurology (01.11.2009)
Get full text
Journal Article